# KEYLYNK-010 (NCT03834519)

> Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus olaparib
- Indication: previously treated metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03834519
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Prostatic Neoplasms
- Interventions: Pembrolizumab; Olaparib; Abiraterone acetate; Prednisone; Enzalutamide; Prednisolone
- Enrollment: 793
- Primary outcome: Overall Survival (OS)
- Primary outcome: Radiographic Progression-Free Survival (rPFS)

## Indexed commentary on KEYLYNK-010 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 16

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keylynk-010-nct03834519

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03834519", "email": "<work email>"}; the inbox owner confirms by the emailed link.